Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

Clin Cancer Res (2008) 14 (14): 4392–4399.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph + chronic myeloid leukemia
  • Barbara Peter
  • Gregor Eisenwort
  • Irina Sadovnik
  • Karin Bauer
  • Michael Willmann
  • Thomas Rülicke
  • Daniela Berger
  • Gabriele Stefanzl
  • Georg Greiner
  • Gregor Hoermann
  • Alexandra Keller
  • Dominik Wolf
  • Martin Čulen
  • Georg E. Winter
  • Thomas Hoffmann
  • Ana‐Iris Schiefer
  • Wolfgang R. Sperr
  • Johannes Zuber
  • Jiří Mayer
  • Peter Valent
American Journal of Hematology (2022) 97 (9): 1215.
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety
  • Mallesh Pandrala
  • Arne Antoon N. Bruyneel
  • Anna P. Hnatiuk
  • Mark Mercola
  • Sanjay V. Malhotra
Journal of Medicinal Chemistry (2022) 65 (16): 10898.
Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation
  • Juan Liu
  • Yuan Zhang
  • Honglin Huang
  • Xiaoyong Lei
  • Guotao Tang
  • Xuan Cao
  • Junmei Peng
Chemical Biology & Drug Design (2021) 97 (3): 649.
Design, synthesis, and biological evaluation of novel bromo-pyrimidine analogues as tyrosine kinase inhibitors
  • Chandrashekar S. Munikrishnappa
  • G.V. Suresh Kumar
  • Richie R. Bhandare
  • Afzal B. Shaik
Arabian Journal of Chemistry (2021) 14 (4): 103054.
The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data
  • Luigia Luciano
  • Mario Annunziata
  • Immacolata Attolico
  • Francesco Di Raimondo
  • Alessandro Maggi
  • Alessandra Malato
  • Bruno Martino
  • Fausto Palmieri
  • Fabrizio Pane
  • Nicola Sgherza
  • Giorgina Specchia
European Journal of Haematology (2020) 105 (1): 3.
Enhanced SNP-sensing using DNA-templated reactions through confined hybridization of minimal substrates (CHOMS)
  • Ki Tae Kim
  • Nicolas Winssinger
Chemical Science (2020) 11 (16): 4150.
2-substituted benzothiazoles as antiproliferative agents: Novel insights on structure-activity relationships
  • Alessandra Ammazzalorso
  • Simone Carradori
  • Rosa Amoroso
  • Inmaculada Fernández Fernández
European Journal of Medicinal Chemistry (2020) 207: 112762.
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study
  • Suzanne Tavitian
  • Madalina Uzunov
  • Emilie Bérard
  • Didier Bouscary
  • Xavier Thomas
  • Emmanuel Raffoux
  • Thibaut Leguay
  • Maria Pilar Gallego Hernanz
  • Ana Berceanu
  • Stéphane Leprêtre
  • Yosr Hicheri
  • Patrice Chevallier
  • Sarah Bertoli
  • Véronique Lhéritier
  • Hervé Dombret
  • Françoise Huguet
Leukemia & Lymphoma (2020) 61 (9): 2161.
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity
  • Ashraf K. El-Damasy
  • Heewon Jin
  • Seon Hee Seo
  • Eun-Kyoung Bang
  • Gyochang Keum
European Journal of Medicinal Chemistry (2020) 207: 112710.
Microfluidic device for expedited tumor growth towards drug evaluation
  • Christopher George Uhl
  • Yaling Liu
Lab on a Chip (2019) 19 (8): 1458.
Direct Amination of Arenes with Azodicarboxylates Catalyzed by Bisulfate Salt/HFIP Association
  • Ren-Jin Tang
  • Pascal Retailleau
  • Thierry Milcent
  • Benoit Crousse
ACS Omega (2019) 4 (5): 8960.
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML
  • Mathias Schneeweiss-Gleixner
  • Konstantin Byrgazov
  • Gabriele Stefanzl
  • Daniela Berger
  • Gregor Eisenwort
  • Chantal Blanche Lucini
  • Susanne Herndlhofer
  • Sandra Preuner
  • Klara Obrova
  • Petra Pusic
  • Nadine Witzeneder
  • Georg Greiner
  • Gregor Hoermann
  • Wolfgang R. Sperr
  • Thomas Lion
  • Michael Deininger
  • Peter Valent
  • Karoline V. Gleixner
EBioMedicine (2019) 50: 111.
A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML
  • Karoline V. Gleixner
  • Irina Sadovnik
  • Mathias Schneeweiss
  • Gregor Eisenwort
  • Konstantin Byrgazov
  • Gabriele Stefanzl
  • Daniela Berger
  • Harald Herrmann
  • Emir Hadzijusufovic
  • Thomas Lion
  • Peter Valent
Leukemia Research (2019) 78: 36.
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells
  • Hui-ying Li
  • Ding-Di He
  • Xiu-Juan Zhao
  • Tong-Yan Sun
  • Quan Zhang
  • Cui-Gai Bai
  • Yue Chen
Bioorganic & Medicinal Chemistry Letters (2018) 28 (4): 700.
Novel targeted therapeutics for MEN2
  • Sara Redaelli
  • Ivan Plaza-Menacho
  • Luca Mologni
Endocrine-Related Cancer (2018) 25 (2): T53.
Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells
  • Jian Chen
  • Qitian Mu
  • Xia Li
  • Xiufeng Yin
  • Mengxia Yu
  • Jing Jin
  • Chenying Li
  • Yile Zhou
  • Jiani Zhou
  • Shanshan Suo
  • Demin Lu
  • Jie Jin
Oncotarget (2017) 8 (25): 40318.
Cascade Amination and Acetone Monoarylation with Aryl Iodides by Palladium/Norbornene Cooperative Catalysis
  • Wai Chung Fu
  • Bin Zheng
  • Qingyang Zhao
  • Wesley Ting Kwok Chan
  • Fuk Yee Kwong
Organic Letters (2017) 19 (16): 4335.
Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors
  • Wei-cong Lin
  • She-pei Tan
  • Sheng-fu Zhou
  • Xiao-jie Zheng
  • Wen-juan Wu
  • Kang-cheng Zheng
Chinese Journal of Chemical Physics (2017) 30 (4): 429.
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
  • Peter Valent
  • Susanne Herndlhofer
  • Mathias Schneeweiß
  • Bernd Boidol
  • Anna Ringler
  • Stefan Kubicek
  • Karoline V. Gleixner
  • Gregor Hoermann
  • Emir Hadzijusufovic
  • Leonhard Müllauer
  • Wolfgang R. Sperr
  • Giulio Superti-Furga
  • Christine Mannhalter
Oncotarget (2017) 8 (14): 23061.
Incidence of T315I mutation in BCR/ABL-positive CML and ALL patients
  • Fatemeh Norozi
  • Javad Mohammadi-asl
  • Tina Vosoughi
  • Mohammad Ali Jalali Far
  • Amal Saki Malehi
  • Najmaldin Saki
Frontiers in Biology (2016) 11 (5): 404.
Visible-Light-Induced Direct Oxidative C−H Amidation of Heteroarenes with Sulfonamides
  • Kun Tong
  • Xiaodong Liu
  • Yan Zhang
  • Shouyun Yu
Chemistry - A European Journal (2016) 22 (44): 15669.
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
  • Pranav Gupta
  • Rishil J. Kathawala
  • Liuya Wei
  • Fang Wang
  • XiaoKun Wang
  • Brian J. Druker
  • Li-Wu Fu
  • Zhe-Sheng Chen
Cancer Letters (2016) 383 (2): 220.
Catalytic Methods for Aromatic C–H Amination: An Ideal Strategy for Nitrogen-Based Functional Molecules
  • Jiao Jiao
  • Kei Murakami
  • Kenichiro Itami
ACS Catalysis (2016) 6 (2): 610.
Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia
  • Shuzhen Wang
  • Weiquan Xie
  • Duowei Wang
  • Zhigang Peng
  • Yan Zheng
  • Nan Liu
  • Wen Dai
  • Yang Wang
  • Zongqiang Wang
  • Yong Yang
  • Yijun Chen
Oncotarget (2015) 6 (14): 12128.
Ponatinib: Accelerated Disapproval
  • Justin F. Gainor
  • Bruce A. Chabner
The Oncologist (2015) 20 (8): 847.
Preclinical model for identification of therapeutic targets for CML offers clues for handling imatinib resistance
  • Poonam R. Molli
  • Madhura B. Pradhan
  • Arvind D. Ingle
  • Nishigandha R. Naik
Biomedicine & Pharmacotherapy (2015) 73: 160.
Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways
  • Jing Li
  • Yingyu Chen
  • Buyuan Chen
  • Cai Chen
  • Binglin Qiu
  • Zhihong Zheng
  • Jing Zheng
  • Tingbo Liu
  • Wenfeng Wang
  • Jianda Hu
Journal of Cancer Research and Clinical Oncology (2015) 141 (2): 283.
Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer
  • Adriana Zámečníkova
Expert Opinion on Drug Discovery (2014) 9 (1): 77.
BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein
  • Pietro Buffa
  • Chiara Romano
  • Alessandro Pandini
  • Michele Massimino
  • Elena Tirrò
  • Francesco Di Raimondo
  • Livia Manzella
  • Franca Fraternali
  • Paolo G. Vigneri
The FASEB Journal (2014) 28 (3): 1221.
Prospective analysis of low-levelBCR–ABL1T315I mutation in CD34 + cells of patients withde novochronic myeloid leukemia
  • Tomas Jurcek
  • Filip Razga
  • Petra Mazancova
  • Milena Musilova
  • Dana Dvorakova
  • Marek Borsky
  • Daniela Zackova
  • Blanka Dobesova
  • Lukas Semerad
  • Jiri Mayer
  • Zdenek Racil
Leukemia & Lymphoma (2014) 55 (8): 1915.
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha
  • Rabab M. El Eit
  • Ahmad N. Iskandarani
  • Jessica L. Saliba
  • Mark N. Jabbour
  • Rami A. Mahfouz
  • Nizar M.A. Bitar
  • Hanadi R. El Ayoubi
  • Ghazi S. Zaatari
  • Francois-Xavier Mahon
  • Hugues B. De Thé
  • Ali A. Bazarbachi
  • Rihab R. Nasr
International Journal of Cancer (2014) 134 (4): 988.
A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells
  • Vijay M. Shahani
  • Daniel P. Ball
  • Allan V. Ramos
  • Zhihua Li
  • Paul A. Spagnuolo
  • Sina Haftchenary
  • Aaron D. Schimmer
  • Suzanne Trudel
  • Patrick T. Gunning
Bioorganic & Medicinal Chemistry (2013) 21 (17): 5618.
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
  • Luca Mologni
  • Sara Redaelli
  • Andrea Morandi
  • Ivan Plaza-Menacho
  • Carlo Gambacorti-Passerini
Molecular and Cellular Endocrinology (2013) 377 (1-2): 1.
Sequence Determinants of a Specific Inactive Protein Kinase Conformation
  • Sanjay B. Hari
  • Ethan A. Merritt
  • Dustin J. Maly
Chemistry & Biology (2013) 20 (6): 806.
Structure-based design of flavone-based inhibitors of wild-type and T315I mutant of ABL
  • Hyeonjeong Choe
  • Jieun Kim
  • Sungwoo Hong
Bioorganic & Medicinal Chemistry Letters (2013) 23 (15): 4324.
Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion
  • Wei Wei
  • He Huang
  • Shan Zhao
  • Wei Liu
  • Chuan-Xu Liu
  • Li Chen
  • Jun-Min Li
  • Ying-Li Wu
  • Hua Yan
Apoptosis (2013) 18 (9): 1060.
Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents
  • Jin Cai
  • Min Sun
  • Xiaoqing Wu
  • Junqing Chen
  • Peng Wang
  • Xi Zong
  • Min Ji
European Journal of Medicinal Chemistry (2013) 63: 702.
Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo Design
  • Hwangseo Park
  • Seunghee Hong
  • Jinhee Kim
  • Sungwoo Hong
Journal of the American Chemical Society (2013) 135 (22): 8227.
Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant
  • Seunghee Hong
  • Jinhee Kim
  • Sun-Mi Yun
  • Hyunseung Lee
  • Yoonsu Park
  • Soon-Sun Hong
  • Sungwoo Hong
Journal of Medicinal Chemistry (2013) 56 (9): 3531.
Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening
  • Hwangseo Park
  • Seunghee Hong
  • Sungwoo Hong
Journal of Computer-Aided Molecular Design (2012) 26 (8): 983.
Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells
  • Jung-Hyun Kim
  • Minjung Song
  • Geun-Ho Kang
  • Eung-Ryoung Lee
  • Hye-Yeon Choi
  • Chung Lee
  • Jin-Hoi Kim
  • Youngsoo Kim
  • Bon-Nyeo Koo
  • Ssang-Goo Cho
Leukemia Research (2012) 36 (9): 1157.
Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis
  • Ji-Youn Youn
  • Andrew Nguyen
  • Hua Cai
Clinical Science (2012) 123 (8): 509.
New insights into small-molecule inhibitors of Bcr-Abl
  • S. Schenone
  • O. Bruno
  • M. Radi
  • M. Botta
Medicinal Research Reviews (2011) 31 (1): 1.
Current status of agents active against the T315I chronic myeloid leukemia phenotype
  • Aine Carol Burke
  • Ronan T Swords
  • Kevin Kelly
  • Francis J Giles
Expert Opinion on Emerging Drugs (2011) 16 (1): 85.
Online Nanoflow Multidimensional Fractionation for High Efficiency Phosphopeptide Analysis
  • Scott B. Ficarro
  • Yi Zhang
  • Marlene J. Carrasco-Alfonso
  • Brijesh Garg
  • Guillaume Adelmant
  • James T. Webber
  • C. John Luckey
  • Jarrod A. Marto
Molecular & Cellular Proteomics (2011) 10 (11): O111.011064.
AP24534 (Ponatinib) : le prochain traitement de la leucémie aiguë lymphoblastique à chromosome Philadelphie ?
  • Xavier Thomas
Bulletin du Cancer (2011) 98 (7): 761.
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy
  • Jean-Claude Chomel
  • Ali G. Turhan
Oncotarget (2011) 2 (9): 713.
Omacetaxine mepesuccinate for the treatment of leukemia
  • Theo Daniel Kim
  • Mareike Frick
  • Philipp le Coutre
Expert Opinion on Pharmacotherapy (2011) 12 (15): 2381.
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
  • Thomas O'Hare
  • Michael W.N. Deininger
  • Christopher A. Eide
  • Tim Clackson
  • Brian J. Druker
Clinical Cancer Research (2011) 17 (2): 212.
Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
  • Wei-Sheng Huang
  • Chester A. Metcalf
  • Raji Sundaramoorthi
  • Yihan Wang
  • Dong Zou
  • R. Mathew Thomas
  • Xiaotian Zhu
  • Lisi Cai
  • David Wen
  • Shuangying Liu
  • Jan Romero
  • Jiwei Qi
  • Ingrid Chen
  • Geetha Banda
  • Scott P. Lentini
  • Sasmita Das
  • Qihong Xu
  • Jeff Keats
  • Frank Wang
  • Scott Wardwell
  • Yaoyu Ning
  • Joseph T. Snodgrass
  • Marc I. Broudy
  • Karin Russian
  • Tianjun Zhou
  • Lois Commodore
  • Narayana I. Narasimhan
  • Qurish K. Mohemmad
  • John Iuliucci
  • Victor M. Rivera
  • David C. Dalgarno
  • Tomi K. Sawyer
  • Tim Clackson
  • William C. Shakespeare
Journal of Medicinal Chemistry (2010) 53 (12): 4701.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2022 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept